EP3377534
Meðhöndlun á lungnakrabbameini með því að nota samsetningu af and-PD-1 mótefni og and-CTLA-4 mótefni
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
18.11.2016EP published:
18.6.2025EP application number:
16819718.4
EP translation filed:
13.8.2025Grant published:
15.9.2025EPO information:
European Patent Register
Max expiry date:
17.11.2036Expiry date:
17.11.2026Next due date:
30.11.2026
Title in English:
TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODYLanguage of the patent:
English
Timeline
Today
18.11.2016EP application
18.6.2025EP Publication
13.8.2025Translation submitted
15.9.2025Registration published
17.11.2026Expires
Owner
Name:
Bristol-Myers Squibb CompanyAddress:
Route 206 and Province Line Road, Princeton, NJ 08543, US
Inventor
Name:
FAITH, Nathan E.Address:
Princeton, New Jersey 08543, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201562257139 PDate:
18.11.2015Country:
US
Number:
201662345314 PDate:
3.6.2016Country:
US
Classification
Categories:
C07K 16/28, A61K 39/00, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 10
Paid: 11.11.2025
Expires: 17.11.2026
Payer: Árnason Faktor ehf.